Rohan Palekar 89bio, Inc. (ETNB) insider trading activity

Rohan Palekar is Chief Executive Officer of 89bio, Inc.. Currently has a direct ownership of 459,171 shares of ETNB, which is worth approximately $3.49 Million. The most recent transaction as insider was on Apr 01, 2024, when has been sold 52,718 shares (Common Stock) at a price of $10.91 per share, resulting in proceeds of $575,153. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 459K

0% 3M change

50.33% 12M change

Total Value Held $3.49 Million

ROHAN PALEKAR Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 01 2024	SELL Open market or private sale	$575,153 $10.91 p/Share	52,718 Reduced 10.3%	459,171 Common Stock
Apr 01 2024	BUY Exercise of conversion of derivative security	$48,250 $1.93 p/Share	25,000 Added 4.66%	511,889 Common Stock
Feb 26 2024	SELL Open market or private sale	$48,172 $10.76 p/Share	4,477 Reduced 0.91%	486,889 Common Stock
Feb 17 2024	SELL Payment of exercise price or tax liability	$44,823 $9.74 p/Share	4,602 Reduced 0.93%	491,366 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$107,061 $8.45 p/Share	12,670 Reduced 2.57%	480,968 Common Stock
Feb 05 2024	SELL Payment of exercise price or tax liability	$49,666 $9.8 p/Share	5,068 Reduced 1.02%	493,646 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	150,000 Added 23.12%	498,714 Common Stock

Jan 05 2024	SELL Payment of exercise price or tax liability	$317,201 $11.53 p/Share	27,511 Reduced 7.31%	348,714 Common Stock
Jan 05 2024	BUY Grant, award, or other acquisition	-	75,000 Added 16.62%	376,225 Common Stock
Dec 29 2023	SELL Open market or private sale	$560,000 $11.2 p/Share	50,000 Reduced 14.24%	301,225 Common Stock
Dec 29 2023	BUY Exercise of conversion of derivative security	$96,500 $1.93 p/Share	50,000 Added 12.46%	351,225 Common Stock
Aug 17 2023	SELL Payment of exercise price or tax liability	$69,585 $15.46 p/Share	4,501 Reduced 1.47%	300,950 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$313,186 $18.95 p/Share	16,527 Reduced 5.13%	305,451 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	-	33,334 Added 9.38%	321,978 Common Stock
Jun 05 2023	SELL Open market or private sale	$300,000 $20.0 p/Share	15,000 Reduced 4.97%	286,978 Common Stock
Jun 05 2023	BUY Exercise of conversion of derivative security	$28,950 $1.93 p/Share	15,000 Added 4.73%	301,978 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$235,196 $15.23 p/Share	15,443 Reduced 5.11%	286,970 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	-	33,333 Added 9.93%	302,413 Common Stock
Mar 23 2023	SELL Open market or private sale	$240,000 $16.0 p/Share	15,000 Reduced 5.28%	269,080 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$87,717 $13.97 p/Share	6,279 Reduced 2.16%	284,072 Common Stock
Feb 09 2023	BUY Grant, award, or other acquisition	-	75,000 Added 20.53%	290,351 Common Stock
Feb 05 2023	SELL Payment of exercise price or tax liability	$53,992 $13.24 p/Share	4,078 Reduced 1.86%	215,351 Common Stock
Sep 28 2022	SELL Payment of exercise price or tax liability	$66,396 $5.76 p/Share	11,527 Reduced 4.99%	219,429 Common Stock
Sep 28 2022	BUY Grant, award, or other acquisition	-	33,333 Added 12.61%	230,956 Common Stock
Sep 08 2022	BUY Exercise of conversion of derivative security	$193,000 $1.93 p/Share	100,000 Added 33.6%	197,623 Common Stock

Also insider at

NLTX

Neoleukin Therapeutics, Inc. Healthcare

Director

Rohan Palekar

Chief Executive Officer

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ETNB shares.

Notify only if

Value

Insider Trading

Get notified when an 89bio, Inc. insider buys or sells ETNB shares.

Notify only if

Operation

Value

Type

News

Receive news related to 89bio, Inc.

Track Activities on ETNB

Account